Clinical Outcomes and Epidemiology of COVID-19

The clinical spectrum of COVID-19 ranges from asymptomatic infection to critical illness characterised by respiratory failure, multi-organ dysfunction and death. Risk factors for severe outcomes include advanced age, male sex and the presence of chronic comorbidities such as cardiovascular disease, diabetes and chronic respiratory conditions. The case fatality rate has varied between settings according to healthcare capacity, demographic structure and public-health interventions, but global mortality exceeded six million by mid-2022. Epidemiological studies have quantified the impact of vaccination, antiviral therapies and non-pharmaceutical measures on virus transmission dynamics and hospital burden. Surveillance of emerging variants continues to inform strategies for mitigation, with equitable vaccine distribution and early diagnosis remaining central to reducing severe disease and mortality worldwide.

Research from Nature Portfolio

Investigations into vaccine responses among populations with high rates of chronic disease have revealed that underlying comorbidities can perturb antibody quality as well as quantity. A study in an Indigenous cohort with renal disease and diabetes demonstrated that aberrant IgG glycosylation patterns are linked to reduced neutralisation titres following standard immunisation schedules. These findings highlight the need for tailored booster strategies in vulnerable groups and underscore the complex interplay between metabolic health and adaptive immunity.

Clinical Outcomes and Epidemiology of COVID-19 publication trend

The graph below shows the total number of articles in clinical outcomes and epidemiology of covid-19 across all publications each year (not limited to Nature Index journals).

Technical terms

Comorbidity: The coexistence of one or more chronic health conditions (such as diabetes or hypertension) alongside the primary disease of interest.

Cohort: A group of individuals followed over time in research to assess how exposures relate to outcomes.

Immunophenotyping: The detailed characterisation of immune-cell populations by surface markers and functional assays.

IgG glycosylation: The attachment of sugar molecules to immunoglobulin G, influencing its stability, effector functions and interaction with immune receptors.

References

1. Immunity to COVID after vaccination in First Nations peoples is affected by comorbidities. Nature Immunology (2023).
2. Multi-omic longitudinal study reveals immune correlates of clinical course among hospitalized COVID-19 patients. Cell Reports Medicine (2023).
3. Estimates of hospitalisations and deaths in patients with COVID-19 associated with undiagnosed diabetes during the first phase of the pandemic in eight low-income and middle-income countries: a modelling study. EClinicalMedicine (2024).